Published January 1, 2022 | Version v1
Journal article Open

Versatile-in-All-Trades: Multifunctional Boron-Doped Calcium-Deficient Hydroxyapatite Directs Immunomodulation and Regeneration

  • 1. Middle East Tech Univ, Dept Engn Sci, TR-06800 Ankara, Turkey
  • 2. Middle East Tech Univ, Dept Biotechnol, TR-06800 Ankara, Turkey

Description

Osseointegration of implants depends on several intertwined factors: osteogenesis, angiogenesis, and immunomodulation. Lately, novel reinforcements allowing faster bonding with osseous tissue have been explored intensively. In this study, we hypothesized the use of boron as a major multifunctional ion to confer versatility to calcium-deficient hydroxyapatite (cHA) synthesized by a wet precipitation/microwave reflux method. By synthesis of boron-doped calcium-deficient hydroxyapatite (BcHA), we expected to obtain an osteoimmunomodulatory and regenerative nanoreinforcement. BcHA was found to possess a pure HA phase, a greater surface area (66.41 m(2)/g, p = 0.028), and cumulative concentrations of Ca (207.87 +/- 6.90 mg/mL, p < 0.001) and B (112.70 +/- 11.79 mg/mL, p < 0.001) released in comparison to cHA. Osteogenic potential of BcHA was analyzed using human fetal osteoblasts. BcHA resulted in a drastic increase in the ALP activity (1.11 +/- 0.11 minol/gDNA.min, p < 0.001), biomineralization rate, and osteogenic gene expressions compared to cHA. BcHA angiogenic potential was investigated using human umbilical cord vein endothelial cells. Significantly, the highest VEGF-A release (1111.14 +/- 87.82 in 4 h, p = 0.009) and angiogenic gene expressions were obtained for BcHA-treated samples. These samples were also observed to induce a more prominent and highly branched tube network. Finally, inflammatory and inflammasome responses toward BcHA were elucidated using human monocyte-derived macrophages differentiated from THP-1s. BcHA exhibited lower CAS-1 release (50.18 +/- 5.52 mu g/g(DNA) mu g/gDNA) and higher IL-10 release (126.97 +/- 15.05 mu g/g(DNA)) than cHA. In addition, BcHA treatment led to increased expression of regenerative genes such as VEGF-A, RANKL, and BMP-2. In vitro results demonstrated that BcHA has tremendous osteogenic, angiogenic, and immunomodulatory potential to be employed as a "versatile-in-all-trades" modality in various bone tissue engineering applications.

Files

bib-0498c6bf-0d7a-4fe7-ad40-98aba6d7250b.txt

Files (230 Bytes)

Name Size Download all
md5:d62f2faa63d025b680c943e432bbd5d9
230 Bytes Preview Download